✓
Open
9 Oct 2025
✓
Close
13 Oct 2025
3
Allotment
—
✓
Listing
Thu, Oct 16, 2025
Price Band
₹461 to ₹485
Issue Size
2,84,05,841 shares (agg. up to ₹1,377 Cr)
Lot Size
30 Shares
Listing Date
Thu, Oct 16, 2025
Latest GMP
₹120
Est. Gain
24.74%
✦ AI Insight
GMP Trend
16-10-2025₹120Est. ₹605+24.74%
15-10-2025₹151Est. ₹636+31.13%
14-10-2025₹128Est. ₹613+26.39%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 60.38x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,647.60 | 1,451.43 | 1,109.49 | 749.70 |
| Total Income | 356.95 | 1,296.22 | 872.39 | 419.00 |
| Profit After Tax | 43.30 | 134.36 | 91.01 | -16.89 |
| EBITDA | 79.74 | 267.89 | 173.09 | 43.97 |
| NET Worth | 593.67 | 540.98 | 385.00 | 286.38 |
| Reserves and Surplus | 397.50 | 525.57 | 369.79 | 281.31 |
| Total Borrowing | 495.78 | 393.17 | 396.41 | 317.91 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹168.00 (+1.44%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹14.73 (-3.22%) |
| Senores Pharmaceuticals Ltd. | Mainboard | ₹582.11 Cr | ₹391 | 39.77 | ₹557.80 | +42.66% | ₹1,405.10 (-3.68%) |
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,272.00 (-1.60%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹240.60 (-3.51%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹67.20 (-8.57%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹282.15 (-2.71%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹278.00 (-1.77%) |
| Accretion Pharmaceuticals Ltd. | SME | ₹29.75 Cr | ₹101 | 21.29 | ₹82.95 | -17.87% | ₹165.65 (-0.21%) |
| Amwill Health Care Ltd. | SME | ₹59.98 Cr | ₹111 | 13.81 | ₹93.25 | -15.99% | ₹43.39 (+3.04%) |
| Sat Kartar Shopping Ltd. | SME | ₹33.80 Cr | ₹81 | 14.87 | ₹161.55 | +99.44% | ₹126.60 (-2.62%) |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹37.60 (-4.93%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company | 310.00 |
| 2 | Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes | 161.27 |
| 3 | Issue Expenses | 79.12 |
| Total | 550.40 |
About Rubicon Research IPO
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations. As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialized products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024. As of June 30, 2025, the company has 17 new products awaiting US FDA ANDA approval and 63 products at various stages of development. As of June 30, 2025, the company marketed over 350 SKUs to 96 customers, including three major wholesalers who, account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organizations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organizations. Beyond the US market, Rubicon Research Limited, directly or through third-party distribution partners, has registered or filed 48 product applications across Australia, the United Kingdom
Contact Details
Rubicon Research Ltd. AddressMedOne House, B-75Road No.33, Wagle EstateThane, Maharashtra, 400604022 61414000investors@rubicon.co.inVisit Website